MedTrace Logo

Effects of Different Dialysis Strategies on Inflammation in COVID-19 Maintenance Hemodialysis Patients

NCT04685447 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-05-17

No results posted yet for this study

Summary

In the course of Coronavirus Disease-19 (COVID-19) uncontrolled inflammation has been related to disease severity and unfavorable outcomes.

Here, the investigators study the longitudinal changes of pro- and anti-inflammatory markers in a population of patients undergoing maintenance hemodialysis (HD) affected by COVID-19, evaluating the potential modulating effects of two different dialysis approaches

Conditions

  • Covid19
  • Hemodialysis Complication
  • Inflammatory Response

Interventions

PROCEDURE

Expanded Hemodialysis for Covid19 maintenance hemodialysis patients

After Covid19 diagnosis participants are randomized to receive Expanded Hemodialysis for two weeks

PROCEDURE

Hemodialysis by protein-leaking dialyzer for Covid19 maintenance hemodialysis patients

After Covid19 diagnosis participants are randomized to receive hemodialysis by protein-leaking dialyzer for two weeks

Sponsors & Collaborators

  • IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

    collaborator OTHER

  • Universita degli Studi di Genova

    lead OTHER

Principal Investigators

  • Francesca Viazzi, MD · Unit of Nephrology, Dept Internal Medicine, Univerity of Genova and San Martino Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-16
Primary Completion
2020-04-20
Completion
2022-05-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04685447 on ClinicalTrials.gov